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Abstract
Background: Both recombinant FSH (r-FSH) and highly-purified, urinary FSH (HP-uFSH) are
frequently used in ovulation induction associated with timed sexual intercourse. Their effectiveness
is reported to be similar, and therefore the costs of treatment represent a major issue to be
considered. Although several studies about costs in IVF have been published, data obtained in low-
technology infertility treatments are still scarce.
Methods: Two hundred and sixty infertile women (184 with unexplained infertility, 76 with CC-
resistant polycystic ovary syndrome) at their first treatment cycle were randomized and included
in the study. Ovulation induction was accomplished by daily administration of rFSH or HP-uFSH
according to a low-dose, step-up regimen aimed to obtain a monofollicular ovulation. A bi- or tri-
follicular ovulation was anyway accepted, whereas hCG was withdrawn and the cycle cancelled
when more than three follicles greater than or equal to 18 mm diameter were seen at ultrasound.
The primary outcome measure was the cost of therapy per delivered baby, estimated according to
a cost-minimization analysis. Secondary outcomes were the following: monofollicular ovulation
rate, total FSH dose, cycle cancellation rate, length of the follicular phase, number of developing
follicles (>12 mm diameter), endometrial thickness at hCG, incidence of twinning and ovarian
hyperstimulation syndrome, delivery rate.
Results: The overall FSH dose needed to achieve ovulation was significantly lower with r-FSH,
whereas all the other studied variables did not significantly differ with either treatments. However,
a trend toward a higher delivery rate with r-FSH was observed in the whole group and also when
results were considered subgrouping patients according to the indication to treatment.
Conclusion: Considering the significantly lower number of vials/patient and the slight (although
non-significant) increase in the delivery rate with r-FSH, the cost-minimization analysis showed a
9.4% reduction in the overall therapy cost per born baby in favor of r-FSH.
Published: 18 July 2006
Reproductive Biology and Endocrinology 2006, 4:38 doi:10.1186/1477-7827-4-38
Received: 01 June 2006
Accepted: 18 July 2006
This article is available from: http://www.rbej.com/content/4/1/38
© 2006 Revelli et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Reproductive Biology and Endocrinology 2006, 4:38 http://www.rbej.com/content/4/1/38
Page 2 of 7
(page number not for citation purposes)
Introduction
In the last decades, follicle-stimulating hormone (FSH)
has assumed a central role in ovulation induction and has
been shown to be highly effective in achieving ovulation
in anovulatory infertile woman as well as in ovulation
induction protocols for subfertile, ovulatory women and
in superovulation for IVF [1]. Various FSH-containing
products, both derived from extraction and purification
from urine or from recombinant in vitro technology, have
been developed in these years.
Recombinant FSH (r-FSH) and urinary FSH (u-FSH) have
been repeatedly compared in trials dealing with superovu-
lation induction for IVF. In some of this studies, r-FSH was
reported to yield a better ovarian response with a higher
number of retrieved oocytes [2-5], and a significantly
lower total FSH dose [2-4,6]. The overall number of
embryos obtained in IVF [2-4,7] and the pregnancy rate,
calculated per started cycle or per transferred embryo,
were also reported to be higher with r-FSH than with HP-
uFSH in some of these studies [3,8].
On the other hand, only a few trials have compared r-FSH
and uFSH in subfertile patients undergoing ovulation
induction associated with intrauterine insemination (IUI)
or timed sexual intercourse [9-14]. The limits of these
studies are mainly two: a) some of them compared r-FSH
to uFSH (and not to the more pure formulation HP-
uFSH) [11-15], and b. some authors have considered as a
group anovulatory, infertile women belonging to WHO
group II without indicating the proportion of clomiphene
citrate (CC)-resistant PCOS patients within the group
[13]. When metanalyzed together, the above mentioned
clinical trials have not allowed to draw definite conclu-
sions about the relative effectiveness of r-FSH and u-FSH
(or HP-uFSH) in patients undergoing low-technology
assisted reproduction therapies [16], indicating the need
for further studies.
From the economical perspective, two studies calculated
the cost-effectiveness of r-FSH and u-FSH treatment in
infertile patients undergoing induction of ovulation asso-
ciated with IUI, and concluded that the urinary prepara-
tion was more cost-effective [17,18]. Even to this respect,
however, conclusive data have not been provided so far.
The present trial was designed to compare the cost of the
therapy with either r-FSH or highly-purified, urinary FSH
(HP-uFSH) in patients submitted to ovulation induction.
Both normoovulatory women with unexplained infertility
and women with CC-resistant polycystic ovary syndrome
(PCOS) were randomized in this prospective study.
Assuming that the effectiveness of the two drugs in terms
of pregnancy rate is similar [11-18], a cost-minimization
analysis considering the cost sustained by the Italian
Health Service for every delivered baby after FSH therapy
was accomplished.
Materials and methods
Patients
Two hundred and sixty women belonging to subfertile
couples undergoing ovulation induction associated with
timed intercourse at the Reproductive Medicine and IVF
Unit of the University of Turin were enrolled in this study.
Their age ranged between 28 and 38 years (mean ± SD
32.7 ± 4.3) and their body mass index (BMI) ranged
between 19 and 26 Kg/m2 (mean ± SD 21.5 ± 3.4); all
were in good physical and mental health with no history
of alcohol and/or drug abuse within the 24 months pre-
ceding the treatment. These patients had a history of cou-
ple's infertility from at least one year (mean ± SD 2.6 ± 1.5
yrs), primary infertility in about 75% of cases, secundary
in about 25%. At a routinary diagnostic workout, patent
tubes and normal uterine cavity were documented in all
patients by a recent (within 1 year) hysterosalpingography
or laparoscopy. A recent (within 2 months) semen analy-
sis of the partner revealed normal semen parameters
according to the World Health Organization standards
[19].
Both normoovulatory patients with unexplained infertil-
ity (n = 184) and CC-resistant PCOS (n = 76) were
included in the study. In the latter patients, CC resistance
was defined as consistent failure to ovulate with incre-
mental dose of CC up to 200 mg/day for 5 days in three
previous treatment cycles.
Study design
This prospective, randomized study aimed to compare the
cost of therapy with either r-FSH (Gonal-F® Serono, Swit-
zerland) or HP-uFSH (Metrodin HP® Serono, Switzerland)
in women undergoing ovulation induction associated
with timed intercourse.
Randomization was performed using a computer-gener-
ated random assignment schedule for each patient and
was accomplished using a blocking method that assured
an equal number of patients in the two treatment groups
as well as a similar proportion of PCOS patients and of
secondary infertility in the two groups. Only the first ovu-
lation induction cycle of each patient was considered in
the study. Overall, a total of number of 130 patients per
group were included.
The treatment cost per delivered baby was considered as
the primary end-point and on this basis the size of the
study population was calculated by power analysis. The
sample size calculation was performed using Graph-Pad
StateMate version 2.0 (GraphPad Software, Inc. USA) asReproductive Biology and Endocrinology 2006, 4:38 http://www.rbej.com/content/4/1/38
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follows. Assuming from evidence of previous studies [9-
12,14,17,18] a total amount of -20% ampules needed to
reach ovulation in favour of r-FSH, the costs fixed by the
Italian Health Service for 100 ampules of HP-uFSH and 80
ampules of r-FSH were calculated. This resulted in -17%
cost in favour of HP-uFSH, assuming the effectiveness of
both preparations to be the same. With such a difference,
130 observations per arm would be needed to have a
detection power of 95% accepting a significance level of
0.05.
The following clinical parameters were used to accom-
plish a cost-minimization analysis (for details see para-
graph below), and were registered as secondary end-
points: monofollicular response rate, total FSH dose, cycle
cancellation rate, length of the follicular phase; number of
follicles between 12 and 17 mm the day of hCG adminis-
tration; diameter of the leading follicle and endometrial
thickness the day of hCG administration, twinning rate,
incidence of ovarian hyperstimulation syndrome and
delivery rate.
The ovulation induction outcome was defined as mono-
follicular when only one follicle ≥ 18 mm without other
follicles ≥ 12 mm diameter was observed the day of hCG
administration. When a bi- or tri-follicular development
was recorded (two or three follicles ≥ 18 mm without
other follicles ≥ 12 mm diameter the day of hCG admin-
istration), the treatment was continued and hCG was
administered, whereas the treatment cycle was cancelled
when more then three follicles developed up to 18 mm
diameter or, conversely, no follicle developed to more
than 12 mm diameter within 28 days of FSH administra-
tion.
Ovulation induction regimen
Ovulation induction was aimed to obtain a monofollicu-
lar development and was accomplished using the low
dose, step-up protocol starting on day 3 of a spontaneous
or progesterone-induced withdrawal bleeding by means
of subcutaneous or intramuscular injections of 75 IU/day
of either r-FSH or HP-uFSH. If no ovarian response was
detected after two weeks, the daily dose was increased to
112.5 IU for one week, and then to 150 IU. The ovarian
stimulation was stopped in case of no ovarian response
after 28 days of FSH administration.
Ovulation induction was monitored by vaginal ultra-
sound every second-third day starting on day 7–9 of the
cycle; in case of no ovarian response with daily dose
increase, ultrasound evaluation was postponed by one
week.
Follicle rupture was induced by intramuscular injection of
10,000 IU human chorionic gonadotropin (hCG; Profasi
HP®, Serono, Switzerland) when the leading follicle
reached 20 mm diameter. Free sexual intercourses were
encouraged from the day of hCG administration onward
only in cases when no more than three follicles bigger
than 17 mm were observed; otherwise, hCG was not
administered and protected sexual intercourse was recom-
mended in order to avoid high-order multiple concep-
tion.
The luteal phase was supported in every case by vaginal
progesterone (Esolut® Angelini, Italy) at a daily dose of
200 mg for 12 days starting on day +2 from hCG admin-
istration.
Pregnancy was assessed by serum hCG assay and con-
firmed by vaginal ultrasound at six weeks of amenorrhea.
All pregnancies that ended with the delivery of a viable
newborn were considered in calculating the delivery rate.
Cost-minimization analysis
The cost-minimization analysis was accomplished consid-
ering the costs of FSH to the Italian Health Service (IHS),
as IHS sustains the cost of FSH for these treatments and it
is delivered free of charge to patients.
The cost of each treatment was calculated considering the
cost per vial (75 IU) at the time of the clinical trial, that
was equal to 23.40 € and 15.55 € for r-FSH and HP-uFSH,
respectively. The economic impact of the other health
resources on IHS in this trial (e.g. ultrasound monitoring)
was the same for both study groups, and thus was not con-
sidered.
The final outcome of the cost-minimization analysis was
to compare the cost of FSH treatment per delivered baby.
Cost-minimization analysis was preferred to cost-effec-
tiveness analysis because it fits better to comparative stud-
ies in which the effectiveness of compared treatments is
assumed to be similar, as previously reported in this case
[11-18]. Sensitivity analysis was performed calculating the
cost per delivery after having considered both the mean
number of FSH vials consumed in each study group and
the delivery rate for started cycle around the 95% confi-
dence interval.
Statistical analysis
The JMP software (version 4.0.4; SAS Corp., Cary, NC)
was used to perform statistical analysis. The parameters
calculated for either HP-uFSH and r-FSH-treated patients
were compared using the two-tailed Student's t test for
independent data and the χ2 test, setting the significance
level at p ≤ 0.05.Reproductive Biology and Endocrinology 2006, 4:38 http://www.rbej.com/content/4/1/38
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Results
A total number of 260 patients were randomized and
included in the study, 130 in the HP-uFSH group and 130
in the r-FSH group; the clinical and endocrine characteris-
tics of the patients in the two study groups were homoge-
neous (Table 1).
Overall, 260 first-attempt treatment cycles were consid-
ered, 130 with HP-uFSH and 130 with r-FSH. Fifty cycles
(19.2% of all) were cancelled, whereas 210 were con-
cluded with hCG administration, among which 178
(68.5%) were monofollicular and 32 (12.3%) were bi-/
trifollicular (Table 2). Thirty pregnancies reaching deliv-
ery were obtained, with an overall delivery rate per started
cycle of 11.5% and for ovulatory cycle of 13.6% (Table 2).
All pregnancies were singleton.
The only parameter that differed significantly between the
two study groups was the total FSH dose, that was signifi-
cantly lower using r-FSH (p < 0.0003; Table 2). The mono-
follicular ovulation rate was not significantly different in
women treated with HP-uFSH and those receiving r-FSH
(66.9% vs. 70.0%, respectively); the same was observed
for cancellation rate (20.8% and 17.7%, respectively) and
proportion of bi-/trifollicular responses (12.3% in both
groups) (Table 2).
Results of normoovulatory patients and PCOS patients
are shown separately in Tables 3 and 4. In both these sub-
groups, the only significant difference was the total FSH
dose, lower when r-FSH was used (Tables 3 and 4).
Although r-FSH showed a higher effectiveness in terms of
delivery rates in both subgroups, it was not significantly
different (Tables 3 and 4).
Both HP-uFSH and r-FSH were very well tolerated by
patients and only one case of local injection-site eri-
ythema was observed after HP-uFSH administration. No
systemic adverse effects were observed and no severe
hyperstimulation syndrome (OHSS) occurred.
Results of cost-minimization analysis are shown in Table
5. Patients treated with r-FSH required a 21.2% lower
number of vials (75 IU) than patients treated with HP-
uFSH group. Considering the 50.5% higher cost per vial of
r-FSH, even with a lower vial consumption/treatment the
cost per cycle in the r-FSH group resulted 18.5% higher
than in the HP-uFSH group (Table 5). Taking into account
the slightly higher (although not significant) effectiveness
of r-FSH in terms of delivered pregnancies, the total
number of FSH vials per delivered baby resulted to be
39.8% lower for patients treated with r-FSH (Table 5), and
the final treatment cost per delivered baby was 9.4% lower
in the r-FSH group (Table 5). In the sensitivity analysis,
Table 1: Main characteristics of patients receiving ovarian 
stimulation by highly purified urinary human follicle stimulating 
hormone (HP-uFSH) or recombinant human follicle stimulating 
hormone (rFSH) (* values are expressed as mean ± SD; ns = not 
significant)
Overall HP-uFSH rFSH p
N. of patients 260 130 130
Age (years) * 32.7 ± 4.3 33.0 ± 3.6 32.3 ± 4.0 ns
BMI (kg/m2) * 21.5 ± 3.4 21.2 ± 3.0 21.3 ± 3.1 ns
Duration of infertility (years) * 2.6 ± 1.5 2.7 ± 1.4 2.5 ± 1.4 ns
Type of infertility (%):
Primary 196 97 (74.6) 99 (76.1) ns
Secondary 64 33 (25.4) 31 (23.9) ns
Indication to treatment (%):
unexplained infertility 184 91 (70.0) 93 (71.5) ns
CC-resistant PCOS 76 39 (30.0) 37 (28.5) ns
LH/FSH * 1.4 ± 0.6 1.3 ± 0.9 1.4 ± 0.9 ns
Testosterone (ng/mL) * 0.6 ± 0.8 0.6 ± 0.5 0.7 ± 0.1 ns
Prolactin (ng/mL) * 17.9 ± 4.1 17.7 ± 4.0 18.3 ± 3.8 ns
Table 2: Overall outcome of stimulation using a "low dose step-up" protocol and comparison between HP-uFSH and r-FSH (* values 
are expressed as mean ± SD; ns = not significant)
overall HP-uFSH rFSH P
N. of patients 260 130 130
N. of stimulation cycles 260 130 130
Total FSH dose (IU) * 733 ± 387 844 ± 305 668 ± 276 .0003
Duration of follicular phase (days) * 12.3 ± 2.5 12.7 ± 2.6 11.7 ± 2.5 ns
No. of preovulatory follicles ≥ 18 mm at hCG * 1.8 ± 1.2 1.9 ± 1.1 1.8 ± 1.2 ns
No. of follicles 12–17 mm at hCG * 3.8 ± 1.6 3.7 ± 1.9 3.8 ± 1.6 ns
Size of the dominant follicle at hCG (mm) * 20.2 ± 1.1 20.1 ± 1.0 20.3 ± 0.9 ns
Endometrial thickness at hCG (mm) * 10.4 ± 1.5 10.8 ± 1.1 9.9 ± 1.8 ns
Monofollicular cycles (%) 178 (68.5) 87 (66.9) 91 (70.0) ns
Bi-/trifollicular cycles (%) 32 (12.3) 16 (12.3) 16 (12.3) ns
Cancelled cycles (%) 50 (19.2) 27 (20.8) 23 (17.7) ns
Deliveries 30 13 17
Delivery rate/started cycle (%) 11.5 10.0 (95%CI: 4.5–15.2) 13.1 (95%CI: 7.3–18.9) ns
Delivery rate/ovulatory cycle (%) 13.6 12.0 15.2 nsReproductive Biology and Endocrinology 2006, 4:38 http://www.rbej.com/content/4/1/38
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the cost for delivered baby resulted to be lower with r-FSH
also after correcting for the confidence interval of delivery
rate, the cost reduction ranging from 2.7% to 21.9% with
rFSH.
Discussion
The technology used to obtain pharmacologically availa-
ble human FSH has traditionally been extraction and
purification from the urine of postmenopausal women.
The purification process has been progressively improved,
finally yielding a highly-purified urinary FSH (HP-uFSH)
with less than 0.001 IU of LH per FSH ampoule and a low
amount of proteinic contamination. The increasing
spread of assisted reproduction techniques that has taken
place all over the world in the last years has rapidly
increased the need of bulk amounts of FSH for therapeutic
use, and a recombinant technology to get theoretically
unlimited amounts of recombinant human FSH (r-FSH)
from cultured cells has been successfully developed [20].
In comparison to uFSH or HP-uFSH, r-FSH has an abso-
lute purity (no LH content, no contamination by pro-
teinic molecules), a higher batch-to-batch consistency,
and no risk of transmission of infectious diseases [20].
However, r-FSH is much more expensive than urinary FSH
on a per-unit basis, and its cost-effectiveness remains con-
troversial, especially for patients undergoing ovulation
induction and low-technology assisted reproduction
treatments [21].
Although r-FSH has been claimed to achieve some advan-
tage in case of IVF treatment (more oocytes, more
embryos available for transfer, a higher pregnancy chance
with a lower total FSH dose and a shorter follicular phase)
[2,4,7,8,22,23], only a few studies have been designed to
compare r-FSH and uFSH in low-technology treatments,
when monofollicular ovulation is preferable. Moreover,
in most of these studies uFSH and not HP-uFSH was used
[11-15,17,18], as only two of them compared rFSH to HP-
Table 3: Outcome of stimulation in normoovulatory patients with unexplained infertility and comparison between HP-uFSH and r-
FSH (* values are expressed as mean ± SD; ns = not significant).
Overall HP-uFSH rFSH P
N. of patients 184 91 93
N. of stimulation cycles 184 91 93
Total FSH dose (IU) * 762 ± 505 837 ± 349 644 ± 199 0.005
Duration of follicular phase (days) * 12.0 ± 2.9 12.4 ± 2.5 11.6 ± 2.1 ns
No. of preovulatory follicles ≥ 18 mm at hCG * 1.2 ± 0.9 1.2 ± 0.8 1.1 ± 0.9 ns
No. of follicles 12–17 mm at hCG * 0.4 ± 0.3 0.4 ± 0.3 0.4 ± 0.3 ns
Size of the dominant follicle at hCG (mm) * 20.5 ± 1.9 20.6 ± 1.8 20.4 ± 1. 8 ns
Endometrial thickness at hCG (mm) * 9.5 ± 2.0 9.6 ± 1.9 9.5 ± 1.5 ns
Monofollicular cycles (%) 150 (81.5) 74 (81.3) 76 (81.7) ns
Bi-/trifollicular cycles (%) 20 (10.9) 10 (11.0) 10 (10.8) ns
Cancelled cycles (%) 14 (7.6) 7 (7.7) 7 (7.5) ns
Deliveries 19 9 10
Delivery rate/started cycle (%) 10.3 9.9 10.7 ns
Delivery rate/ovulatory cycle (%) 11.2 10.7 11.6 ns
Table 4: Outcome of stimulation in patients with clomiphene citrate-resistant polycystic ovary syndrome and comparison between 
HP-uFSH and r-FSH (* values are expressed as mean ± SD; ns = not significant)
Overall HP-uFSH rFSH P
N. of patients 76 39 37
N. of stimulation cycles 76 39 37
Total FSH dose (IU) * 648 ± 498 833 ± 307 546 ± 346 0.002
Duration of follicular phase (days) * 12.1 ± 3.9 11.9 ± 3.6 12.2 ± 3.7 ns
No. of preovulatory follicles ≥ 18 mm at hCG * 2.0 ± 0.9 2.0 ± 0.8 2.0 ± 0.9 ns
No. of follicles 12–17 mm at hCG * 4.2 ± 2.1 4.2 ± 2.0 4.1 ± 1.9 ns
Size of the dominant follicle at hCG (mm) * 20.8 ± 1.8 20.8 ± 1.6 20.9 ± 1. 7 ns
Endometrial thickness at hCG (mm) * 10.7 ± 2.0 10.9 ± 1.7 10.5 ± 1.9 ns
Monofollicular cycles (%) 28 (36.8) 13 (33.3) 15 (40.5) ns
Bi/trifollicular cycles (%) 12 (15.8) 6 (15.4) 6 (16.2) ns
Cancelled cycles (%) 36 (47.4) 20 (51.3) 16 (43.2) ns
Deliveries 11 4 7
Delivery rate/started cycle (%) 14.5 10.3 18.9 ns
Delivery rate/ovulatory cycle (%) 27.5 21.1 33.3 nsReproductive Biology and Endocrinology 2006, 4:38 http://www.rbej.com/content/4/1/38
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uFSH in low-technology ART [9,10]. Furthermore, WHO
group II anovulatory women were considered by some
authors as an homogeneous group, without calculating
the proportion of CC-resistant PCOS patients within the
studied population [13]. When available data were
pooled together and metanalyzed, no conclusive results
could be found, and the need for further studies compar-
ing r-FSH and uFSH was underlined [16].
In the present study, an FSH low dose, step-up protocol
was adopted in order to get preferably monofollicular
ovulation (with a few cases having two/three preovulatory
follicles); all patients having more than three preovula-
tory follicles were discouraged to conceive: this mini-
mized the risk of multiple pregnancy and ovarian
hyperstimulation syndrome even in high-risk patients
(e.g. young CC-resistant PCOS patients). Overall, a high
proportion of ovulatory cycles and a high rate of monofol-
licular ovulation was obtained with either FSH formula-
tion, very frequently (about 90% of cases) in
normoovulatory women with unexplained infertility, in
about 50% of cases in patients with CC-resistant PCOS,
which are known to have a well defined trend toward
multifollicular recruitment. In contrast with some of the
reports comparing r-FSH to uFSH [12,13], we did not
observe any significant difference between r-FSH and HP-
uFSH as far as the cycle cancellation rate and the monofol-
licular ovulation rate are concerned. Probably the higher
purity of HP-uFSH with respect to the less purified uFSH,
and the consequent lower interference produced by LH
and other proteinic contaminants over the dominant fol-
licle selection, explains the discrepancy between previous
studies [12,13] and ours. Indeed, our results are similar to
those obtained by Matorras et al., that compared HP-
uFSH to r-FSH in normoovulatory women undergoing IUI
[10].
Consistently to previous reports [9-12,14,17,18], the total
FSH dose necessary to achieve ovulation was significantly
lower using r-FSH. The reason for this can likely be found
in the higher biological potency of r-FSH, in turn linked to
the more basic spectrum of isoforms that gives more
receptor binding affinity to the molecule, as well as to the
lower proportion of degraded FSH forms in r-FSH [24].
An alternative possibility is that r-FSH could be more
active in inducing the synthesis of intraovarian factors
(e.g. Inhibin A) able to amplify the effects of FSH at the
ovarian level [25].
Consistently with previously published reports
[9,10,12,13,17,18] the results in terms of deliveries per
started cycle and per ovulatory cycle were not significantly
different with either r-FSH or HP-uFSH, although the
delivery rate was slightly higher with the recombinant
product. The cancellation of every cycle in which more
than three preovulatory follicles were developed pre-
vented our patients from experiencing twin pregnancies or
ovarian hyperstimulation syndrome, that are unlikely
when less than four follicles are developed.
Since both r-FSH and HP-uFSH allow to achieve compara-
ble results in low-technology cycles, the cost of therapy is
a major issue to be considered. In IVF, the overall cost per
successful pregnancy resulted to be significantly lower
with r-FSH, due to its higher effectiveness [26]. However,
in low-technology treatments like ovulation induction
plus timed intercourse, the pregnancy rate is not signifi-
cantly higher using r-FSH, and therefore the final cost per
delivered baby using HP-uFSH or r-FSH needs a careful
evaluation. Two recent studies calculated the cost-effec-
tiveness of treatments with r-FSH or u-FSH in infertile
patients undergoing induction of ovulation associated
with IUI, and concluded that the urinary preparation was
more cost-effective [17,18]. However, the cost-minimiza-
tion analysis fits better to analyze costs in comparative
studies in which the treatment effectiveness of the studied
drugs is very similar, as in this case [11-18].
In our prospective, randomized trial the total number of
FSH vials per delivered baby was about 40% lower among
patients treated with r-FSH. For this reason and for the
slightly higher delivery rate in the r-FSH group, even con-
sidering the higher cost per vial of r-FSH, the final cost per
delivery was estimated 9.4% lower with r-FSH. The eco-
nomical advantage of r-FSH was confirmed even when the
confidence interval of delivery rate was considered in a
sensitivity analysis; in fact, even after correction, the cost
reduction per delivered baby was still ranging from 2.7%
to 21.9% in favor of r-FSH.
It must be remarked that differently from the previously
published cost-effectiveness studies [17,18], in our study
Table 5: Cost-minimization analysis and (last row) percentage variation of economical parameters in r-FSH vs. HP-uFSH treatment
Mean FSH IU/
cycle (95%CI)
Mean n. of 
vials/cycle 
(95%CI) (A)
Cost per vial 
(€) (B)
Mean cost/
cycle (€) (C) 
= (A) × (B)
Total n. of vials 
(95%CI) (D) = (A) × 
130
N. of 
deliveries 
(95%CI) (E)
Total n. of 
vials/delivery 
(F) = (D)/(E)
Cost per 
delivery (€) 
(B) × (F)
HP-uFSH 844 (741–947) 11.3 (9.9–12.6) 15.55 175.71 1,469 (1,287–1,638) 13 (6–20) 113 (214–82) 1,757.15
r-FSH 668 (575–761) 8.9 (7.7–10.1) 23.40 208.26 1,157 (1,001–1,313) 17 (9–25) 68 (111–53) 1,591.20
% -20.8 -21.2 +50.5 +18.5 -21.2 +30.8 -39.8 -9.4Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Reproductive Biology and Endocrinology 2006, 4:38 http://www.rbej.com/content/4/1/38
Page 7 of 7
(page number not for citation purposes)
only first-treatment cycles were considered, Hp-uFSH
(and not u-FSH) was used, mainly normal (and not all
PCOS) patients were included, and the delivery rate (and
not just the clinical pregnancy rate) was considered as the
best clinical outcome indicator.
In conclusion, the present study shows that both HP-
uFSH and r-FSH can be safely and effectively used to
induce ovulation induction both in normoovulatory
patients with unexplained infertility and in CC-resistant
PCOS patients. The slightly higher effectiveness of r-FSH
in terms of delivered babies seems to compensate for the
higher cost per IU, leading to lower final economical costs
per delivered baby.
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